New drug BI 3031185 tested for safety in BPD and ADHD patients

NCT ID NCT07001475

Completed Symptom relief Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 6 times

Summary

This early-stage study tests whether a new medicine called BI 3031185 is safe and well-tolerated in adults with borderline personality disorder (BPD) or attention-deficit/hyperactivity disorder (ADHD). About 96 participants will receive either the drug or a placebo in a crossover design, with close monitoring for side effects over 1-2 months. The goal is to gather initial safety data, not to treat the conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder borderline personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION DEFICIT HYPERACTIVITY DISORDER BORDERLINE PERSONALITY DISORDER

Contacts and locations

Locations

Charité Research Organisation GmbH

Berlin, 10117, Germany
Martin-Luther-Universität Halle-Wittenberg

Halle, 06112, Germany
Rheinhessen-Fachklinik Mainz

Mainz, 55122, Germany
Universitätsklinikum Bonn AöR

Bonn, 53127, Germany
Universitätsklinikum Frankfurt

Frankfurt am Main, 60590, Germany
Universitätsklinikum Tübingen

Tübingen, 72076, Germany
Zentralinstitut für seelische Gesundheit

Mannheim, 68159, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.